Close Menu
NEW YORK – Qiagen said on Friday that it will receive $598,000 in funding from the US Department of Health and Human Services to develop a version of its QiaStat-Dx Respiratory Panel that will be able to differentiate the novel coronavirus SARS-CoV-2 from 21 other common respiratory pathogens.
 
The funding is being provided through a streamlined process called an easy broad agency announcement (EZ-BAA), which is managed by the HHS Office of the Assistant Secretary for Preparedness and Response's (ASPR's) Biomedical Advanced Research and Development Authority (BARDA).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.